Biogen/$BIIB
Biogen jumps after beating Q4 adjusted EPS and revenue estimates and guiding FY26 EPS $15.25–16.25 above $14.92 consensus.
15 hours ago·Lightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Ticker
$BIIB
Sector
Primary listing
Employees
7,605
Headquarters
Website
Biogen Metrics
BasicAdvanced
$30B
22.89
$8.79
-
-
Price and volume
Market cap
$30B
52-week high
$202.41
52-week low
$110.04
Average daily volume
1.5M
Financial strength
Current ratio
2.679
Quick ratio
1.697
Long term debt to equity
36.026
Total debt to equity
36.026
Profitability
EBITDA (TTM)
3,248.9
Gross margin (TTM)
75.69%
Net profit margin (TTM)
13.07%
Operating margin (TTM)
24.96%
Effective tax rate (TTM)
16.94%
Revenue per employee (TTM)
$1,300,000
Management effectiveness
Return on assets (TTM)
5.37%
Return on equity (TTM)
7.39%
Valuation
Price to earnings (TTM)
22.887
Price to revenue (TTM)
2.98
Price to book
1.62
Price to tangible book (TTM)
11.41
Price to free cash flow (TTM)
14.596
Free cash flow yield (TTM)
6.85%
Free cash flow per share (TTM)
13.783
Growth
Revenue change (TTM)
2.22%
Earnings per share change (TTM)
-21.38%
3-year revenue growth (CAGR)
-0.94%
10-year revenue growth (CAGR)
-0.84%
3-year earnings per share growth (CAGR)
-25.04%
10-year earnings per share growth (CAGR)
-5.42%
What the Analysts think about Biogen
Analyst ratings (Buy, Hold, Sell) for Biogen stock.
Biogen Financial Performance
Revenues and expenses
Biogen Earnings Performance
Company profitability
Biogen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biogen stock?
Biogen (BIIB) has a market cap of $30B as of February 07, 2026.
What is the P/E ratio for Biogen stock?
The price to earnings (P/E) ratio for Biogen (BIIB) stock is 22.89 as of February 07, 2026.
Does Biogen stock pay dividends?
No, Biogen (BIIB) stock does not pay dividends to its shareholders as of February 07, 2026.
When is the next Biogen dividend payment date?
Biogen (BIIB) stock does not pay dividends to its shareholders.
What is the beta indicator for Biogen?
Biogen (BIIB) does not currently have a Beta indicator.